Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
9:30 am - Wednesday 1st April 2026
- Highlighting how locally bioactivated pharmacology and translational biomarker science are converging to redefine the treatment of fibrostenotic IBD
